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Abstract
Background: Previous studies have shown that tuberculosis (TB) is a risk factor for chronic airflow limitation.
Chronic obstructive pulmonary disease (COPD) is recognized as the result of chronic inflammation, usually related
to noxious particles. Post-TB airflow obstruction and tobacco-related COPD have the same functional pathway
characterized by persistent airflow limitation. We sought to compare the profile of 29 cytokines in the sputum of
subjects with post-TB airflow obstruction and those with COPD related to tobacco.
Results: The forced expiratory volume in the first second (FEV1) and forced expiratory volume/forced vital capacity
(FEV/FVC) ratio were lower in the COPD patients with the history of smoking compared to the post-TB airflow
obstruction subgroup. The stages of the disease were more advanced in COPD / tobacco patients.
Among the cytokines, IL-1α, IL-1β, MIP-1β, sCD40L and VEGF levels were higher in COPD patients, compared to the
controls with p values of 0.003, 0.0001, 0.03, 0.0001 and 0.02 respectively. When the two COPD subgroups were
compared, IL-1α, IL-6, TNF-α and IL-8 levels were higher in the COPD patients with the history of tobacco
compared to the COPD patients with the history of TB with p-values of 0.031, 0.05, 0.021 and 0.016, respectively.
Conclusion: COPD related to tobacco is more severe than post-TB airflow obstruction. The pathogenesis of post-TB
airflow obstruction appears to involve the cytokines IL-1RA, IL-1α, IL-1β, IL-17, GRO and sCD40L, while COPD related
to tobacco involves more cytokines.
Keywords: Bronchial obstruction, Cells, COPD, Cytokines, Inflammation, Tobacco, Tuberculosis
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: guiedemelise86@yahoo.fr
1Center for the Study and Control of Communicable Diseases (CSCCD),
Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1,
Yaoundé, Cameroon
Full list of author information is available at the end of the article
Guiedem et al. BMC Immunology           (2020) 21:52 
https://doi.org/10.1186/s12865-020-00381-w
Background
Chronic obstructive pulmonary disease (COPD) is a
respiratory disease characterized by progressive airflow
obstruction that is not fully reversible, with combined
emphysema and chronic obstructive bronchitis [1]. It is
a major cause of morbidity and mortality worldwide and
is gradually increasing. It can lead to abnormal inflam-
mation in the airways. The diagnosis of COPD is based
mainly on clinical symptomatology and measurement of
spirometric variables. Clinical symptomatology include:
evocative signs of chronic bronchial diseases (recurring
bronchial episodes, wheezes) and chronic respiratory
signs (cough, expectoration, effort dyspnea) [1]. The
spirometric diagnosis of COPD include the forced
expiratory volume in the first second (FEV1), the forced
vital capacity (FVC) and FEV/FVC ration. COPD is de-
fined as the FEV/FVC ratio less than 70%, or the lower
limit of normal, after inhalation of 400 μg of salbutamol
and the absence of complete reversibility. The severity of
the COPD is evaluated according to four clinical stages:
Stage I (mild) with FEV1 ≥ 80%, Stage II (moderate) with
50% ≤ FEV1 < 80%, Stage III (severe) with 30% ≤ FEV1 <
50% and Stage IV (very severe) with FEV1 < 30% [2].
Cigarette smoking is known as the main risk factor of
COPD [2]. The defense system of the respiratory airways
includes the mucociliary carpet, which cleans respiratory
airways, and the epithelial tight junctions, which form a
physical barrier between tissues and airway space. This
barrier can be broken by chronic exposure to cigarette
smoke, which irritates the lung wall by damaging epithe-
lial cells and tissue [3]. TNF-α produced by Alveolar
macrophages and epithelial cells, stimulates the influx of
neutrophiles and others monocytes/macrophages to the
airway tract. Macrophages and epithelial cells will se-
crete cytokines such as IL-8, GRO, MCP-1 and MIP-1 α
[4]. These cytokines have several actions in the physio-
pathology of COPD and then subsequently amplify the
inflammatory process during disease [3, 4].
The damage induced by cigarette smoke leads to the
limitation of respiratory flow that induces emphysema
and chronic bronchitis that are peculiar to COPD.
Although smoking is the main cause of COPD [5], the
same functional syndromes, characterized by persistent
airflow obstruction, are increasingly observed in patients
with previous pulmonary tuberculosis (TB) who are non
smokers [6]. Some studies have shown that TB is a risk
factor for COPD, with COPD observed in approximately
7.6% of patients who previously had TB [6, 7]. Other
studies have identified post-TB airflow obstruction in
patients who have a similar syndrome, with a history of
pulmonary TB and have never smoked.
Post-TB airflow limitation is also common after TB
treatment [8]. Inflammation of the bronchial endothelium
leads to localized or generalized bronchial obstruction,
hypertrophy of the submucous glands and smooth mus-
cles, pulmonary fibrosis and edema of airways mucosa,
with increased secretion of mucus [9]. The results of these
events increase airway resistance to airflow [10]. The de-
struction of the parenchyma affects lung compliance by
increasing the tendency of small pathways to collapse, the
main characteristic of COPD [11].
Knowledge of the inflammatory characteristics of
COPD and/or post-TB AFO could help to better adapt
the anti-inflammatory treatment of patients, and thus re-
duce the frequent phenomenon of corticoresistance [12].
The purpose of this study was to determine the profile
of cytokines in COPD patients, with a history of smok-
ing compared to those with a history of TB.
Results
Demographic characteristics
A total of 150 participants were recruited: 90 COPD
patients and 60 clinically healthy non-smokers for the
control group. The COPD patients consisted of 50
patients with a history of smoking (COPD/tobacco) and
40 patients who previously had TB (COPD/post-TB)
(Table 1). A significant difference was observed between
COPD patients with a history of smoking and the
patients with post-TB airflow obstruction with regards
to sex and age, with p values of 0.0023 and 0.0002,
respectively. A multivariate analyzes indicated that spiro-
metric data were not influenced by the sex and age, with
the following results: for the sex, odd ratio (IC 95%) =
2.0 (1.05–10.71) and p = 0.54; for the age, odd ratio =
2.74 (1.15–109.3) and p value of 0.51.
Spirometric characteristics
In the COPD patients with a smoking history, FEV1
ranged from 20.3 to 64.6% and in the post-TB airflow
obstruction patients, FEV1 ranged from 30.0 to 79.0%.
In the control group, FEV/FVC ranged from 70.0 to
97%. The FEV/FVC ratio of COPD/tobacco patients
ranged from 35.0 to 68.0% and in the post-TB airflow
obstruction patients, it ranged from 35.0 to 74.4%. The
FEV1 and FEV/FVC ratio was lower in the COPD
patients with a history of tobacco than in the post-TB
airflow obstruction patients with p-values of 0.014 and
0.033, respectively. As a result, the stage of COPD was
more advanced in COPD patients with a smoking
history compared to COPD patients with anterior TB
with a p-value of 0.032 (Table 1).
Concentrations of cytokines in participants
The detected cytokines in the sputum were anti-
cytokines (IL-1RA), pro-inflammatory cytokines (IL-1α,
IL-1β, IL-6, IL-17 and TNF-α), chemokines (MCP-1, IL-
8, MIP-1α, MIP-1β, GRO, IP-10 and sCD40L) and
growth factors (VEGF, G-CSF and GM-CSF). Other
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cytokines such as IFN-α, IFN-γ, IL-10, IL-12, MDC,
PDGF, IL-15, IL-2, IL-4, IL-7 and RANTES were not de-
tected in the sputum of either the COPD patients or the
control group.
Table 2 shows the mean (± SD) concentrations of
cytokines in sputum in the three groups: in patients with
COPD, the levels of cytokines such as IL-1RA, IL-1α, IL-
1β, MIP-1β, sCD40L and VEGF were statistically higher
compared to the control group with p-values all lower at
0.05. IL-6 and TNF-α were higher in COPD patients
with a history of tobacco compared to the post-TB
airflow obstruction patients and to the control. GRO
concentration was higher in COPD patients with anter-
ior TB than in the control. There were no statistically
significant differences in cytokine concentrations, such
as IL-17, GM-CSF, G-CSF, MIP-1α and IP-10.
Figure 1 show the variation of cytokines and the com-
parison of their concentration using the Student’s T-test
Table 1 Demographic and spirometric data of all participants
COPD/post-TB COPD/tobacco Control p
Age 40 ± 2.1 63 ± 10.45 43 ± 12.38 0.0002
Male 16 (40%) 42 (84%) 40 (66.7%) 0.002
Female 24 (60%) 8 (16%) 20 (33.3%)
FEV1 53.30% (± 17.21%) 36.88% (± 14.95%) 83 ± 6.56% < 0.0001
FVC 84.89 ± 15,1% 72.97 ± 14.5% 97.64 ± 4.15% < 0.0001
FEV1/FVC 62.79% (± 17.95%) 50.54% (± 12.09%). 85 ± 6.06% < 0.0001
Stage of disease Stage I: 0 Stage I: 0 0.038
Stage II: 20 (50%) Stage II: 11 (22%)
Stage III: 15 (37.5%) Stage III: 14 (28%)
Stage IV: 5 (12.5%) Stage IV: 25 (50%)
FEV1 Forced expiratory volume in the first second, FVC Forced vital capacity, FEV1/FVC Forced expiratory volume/ forced vital capacity ratio
Table 2 Sputum cytokine concentrations in patients and controls
Cytokines COPD/post-TB COPD/tobacco Control p
Anti-cytokines (pg/mL)
IL-1RA 1945 (±873.1) 1720 (±491.1) 637.7 ± 191.3 0.046
Pro-inflammatory cytokines (pg/mL)
IL-1 α 821.2 ± 205.7 1555 ± 360.7 539.1 ± 198.6 0.003
IL-1β 137.9 ± 65.25 296.4 ± 143.5 9.410 ± 3.781 < 0.0001
IL-6 9.966 ± 6.916 16.23 ± 7.768 11.64 ± 2.90 0.04
IL-17A 2.412 ± 0.41 1.54 ± 0.2650 1.421 ± 0.23 0.141
TNF-α 1.110 ± 0.5649 7.112 ± 4.542 1.880 ± 0.31 0.0095
Chemokines (pg/mL)
MCP-1 254.3 ± 101.4 657.8 ± 276.3 522.7 ± 69.00 0.08
IL-8 103.0 ± 68.58 493.1 ± 244.9 135.5 ± 30.93 0.023
MIP-1 α 11.12 ± 6.6 10.20 ± 4.9 23.64 ± 6.2 0.1674
MIP-1β 224.1 ± 103.4 181.1 ± 63.57 81.65 ± 20.27 0.03
GRO 14,047 ± 13,020 1721 s ± 977.7 2563 ± 1617 0.05
IP-10 420.8 ± 239.5 242.2 ± 123.9 848.4 ± 314.0 0.069
sCD40L 1.958 ± 0.384 1.506 ± 0.441 0.286 ± 0.164 < 0.0001
Growth factors (pg/mL)
VEGF 333.9 ± 136.5 435.2 ± 130.2 332 ± 155.8 0.02
G-CSF 237.1 ± 146.4 592.3 ± 227 774.3 ± 207.9 0.68
GM-CSF 1.920 ± 0.35 592.3 ± 400.6 1.55 ± 0.35 0.34
Meaning of abbreviations: pg/mL Picogram per milliliter, IL Interleukin, IL-1RA IL-1 receptor antagonist, TNF Tumor necrosis factor, GRO Growth regulated
oncogene, G-CSF Ganulocyte-Colony Stimulating Factor, GM-CSF Granunocyte Macrophage- CSF, IP Interferon-inductible protein, MIP Macrophage inflammatory
protein, MCP Monocyte chemotactic protein, sCD40L Soluble cluster differentiation 40 ligand, VEGF Vascular endothelium growth factor
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or Mann-Whitney U test. When the two subgroups of
COPD patients were compared with each other, the
levels of IL-1α, IL-6, TNF-α and IL-8 were higher in the
COPD patients with a tobacco history than in the
patients with post-TB airflow obstruction with p-values
of 0.031; 0.049; 0.021 and 0.016 respectively, with no
significant differences on the other cytokines (Fig. 1).
The comparison of COPD patients with the history of
smoking to the control group indicated that in COPD/
tobacco patients, the levels of cytokines, such as IL-1RA,
Fig. 1 Variation of cytokines and comparison of their concentrations between two groups. a: Concentration of IL-1RA. b: Concentration of IL-1α.
c: Concentration of IL-1β. d: Concentration of IL-6. e: Concentration of IL-17. f: Concentration of TNF-α. g: Concentration of IL-8. h: Concentration
of MIP-1β. i: Concentration of GRO. j: Concentration of sCD40L. k: Concentration of VEGF. Legend: : Comparison between 2 groups. *:
significant difference. **: non significant difference. IL: interleukin. IL-1RA: IL-1receptor antagonist. GRO: growth regulated oncogene. TNF: tumor
necrosis factor. MIP: macrophage inflammatory protein. MCP: monocyte chemiotactic protein. sCD40L: soluble cluster differentiation 40 ligand.
VEGF: vascular endothelial growth factor. - The Significant difference means that the concentration of the cytokine between the two groups
compared is statistically different with a p value less than or equal to 0.05. - The Non significant difference means that the concentration of
cytokine between the two groups compared is not statistically different with a p value greater than 0.05
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IL-1α, IL-1β, IL-6, TNF-α, IL-17, IL − 8 MIP-1β and
VEGF, were statistically higher compared to the control
group, with p-values of 0.014; 0.006; 0.025; 0.033; 0.048,
0.041; 0.009, 0.012 and 0.035 respectively (Fig. 1), without
statistically significant differences in the concentrations of
cytokines, such as IP-10, MCP-1, GRO, sCD40L, G-CSF
and GM-CSF (Fig. 1).
The comparison of COPD patients with the history of
tuberculosis with the control group showed that the
concentrations of six cytokines, IL-1RA, IL-1β, IL-1α,
IL-17, GRO and sCD40L were higher in patients with
the history of tuberculosis with p-values of 0.014; 0.048;
0.029; 0.045; 0.028 and 0.0013, respectively (Fig. 1), with-
out statistically significant difference in the levels of the
other cytokines, such as G-CSF, GM-CSF, MIP-1α, MIP-
1β, MCP-1, IL-6, TNF-α, IP-10, IL-8, and VEGF between
the control group and COPD with anterior TB (Fig. 1).
Correlation between clinical stage, cells and cytokine
levels in sputum
Figure 2 shows the significant correlations between cyto-
kines and spirometric data or cells in the COPD patients
with a history of smoking. The significant correlations
were: The lower the FEV1 was, the higher the concen-
trations of sCD40L, IL-1α and IL-1β were (Fig. 2). The
lower the FEV/FVC ratio was, the higher the concentra-
tions of sCD40L, IL-1α and IL-1β were (Fig. 2). The
more advanced the clinical stage was, the higher the IL-
1α and IL-1β concentrations were, with correlation
coefficients of 0.295 and 0.384 respectively and p-values
below 0.05 (Fig. 2). Statistically significant positive
correlations were found between neutrophils levels and
cytokines IL-1β and sCD40L, between lymphocytes and
IL-1α and between monocytes and sCD40L (Fig. 2). The
non significant correlations were: There were negative
non significant correlations between FEV1 and cytokines
IL-17, IL-6, MIP-1α, MIP-1β and IL-8. There were nega-
tive non significant correlations between FEV/FVC ratio
and cytokines IL-17, MIP-1α and IL-8. There were posi-
tive non significant correlations between clinical stage
and cytokines GRO, sCD40L, IL-17, IL-6, MIP-1β and
IL-8. The positive non significant correlations were
found between neutrophils and IL-1α, between lympho-
cyte and cytokines such as sCD40L, IL-6, MIP-1β and
TNF-α and between monocytes and cytokines such as
IL-17, IL-1β, IL-1α and IL-8.
Figure 3 shows the significant correlations between cy-
tokines and spirometric data or cells in the patients with
post-TB airflow obstruction: The significant correlations
were: The lower the FEV1 was, the higher the concen-
tration of IL-1α was (Fig. 3). The lower the FEV/FVC
ratio was, the higher the concentrations of IL-1α and
TNF-α were (Fig. 3). The more advanced the clinical
stage was, the higher the IL-17 and IL-6 concentrations
were, with correlation coefficient of 0.489 and 0.401 with
p-values of 0.013 and 0.047. Statistically significant
positive correlation was found between lymphocytes
levels and MIP-1α (Fig. 3: Fig. 3g). The non significant
correlations were: There were negative non significant
correlations between FEV1 and cytokines such as IL-17,
IL-1β, IL-6, MIP-1α, MIP-1β, TNF-α and IL-8. There
were negative non significant correlations between FEV/
FVC ratio and cytokines such as GRO, sCD40L, IL-1β,
IL-6, MIP-1α MIP-1β and IL-8. There were positive non
significant correlations between clinical stage and cyto-
kines such as: GRO, sCD40L, IL-1β, IL-1α, MIP-1α,
MIP-1β, TNF-α and IL-8. The positive non significant
correlations were found: between neutrophils and cyto-
kines sCD40L, IL-1β and MIP-1β, between lymphocyte
and cytokines IL-17, IL-1α, IL-6, MIP-1α, MIP-1β, TNF-
α and IL-8 and between monocytes and cytokines
sCD40L, IL-1β, IL-1α, IL-6, TNF-α and IL-8.
Discussion
We analyzed the spirometric characteristics, cell profile
and cytokine profile in COPD patients with a history of
tobacco, with a history of previous TB and in healthy
participants who served as a control group. This is
significant and relevant because we observed important
differences.
Concerning spirometric characteristics, FEV1 and
FEV/FVC were lower in the COPD patients with a
smoking history than in the COPD patients with post-
TB airflow obstruction. COPD patients with a history of
tobacco were at a more advanced stage of the disease.
These results suggest that the disturbances and irrita-
tions caused by smoking are more pronounced than
those induced by TB. In addition, the treatment of TB
eliminates mycobacterial infection and the damage asso-
ciated with the mycobacterium itself is reduced, while in
smokers, smoking continues to cause damage until the
development of COPD [13]. Moreover, the duration of
smoking and the time being treated for TB may also in-
duce this difference of severity between sub-groups of
COPD patients.
Cytokines of the IL-1 family intervene in the inflam-
matory process [14]; IL-1α, IL-1β and IL-1RA were
assayed. Levels of IL-1α were statistically higher in the
COPD patients with a history of smoking compared to
post-TB subgroup. The study found through association
tests that IL-1α was strongly correlated with the clinical
stage of the disease. Since the stage of COPD was more
advanced in the COPD subgroup with a history of smok-
ing, this could justify the greater presence of IL-1α in
smokers compared to patients with post-TB airflow
obstruction. IL-1RA, IL-1α and IL-1β were higher in the
COPD patients with a smoking history and post-TB
airflow obstruction subgroups, in comparison to the
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Fig. 2 (See legend on next page.)
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control group, with statistically significant differences.
The results for post smoking COPD were similar to
those found by Fernando et al. [14] that showed a strong
IL-1β expression following exposure to tobacco smoke.
In a study by Rusznak et al. [13], they noted significant
secretion of IL-1β by epithelial cells cultured from
COPD patients with a history of smoking. IL-1RA (IL-1
receptor antagonist) is a cytokine inhibitor present in all
cells that express IL-1, more particularly by monocytes/
macrophages, and has an anti-inflammatory role [15].
Since there is bronchial hyperactivity during COPD, IL-
1RA is increased in patients, most likely with the aim of
reducing the effect of high concentrations of IL-1α and
IL-1β [16, 17] at the origin of this hyperactivity, hence
the high concentrations in COPD patients who previ-
ously had TB and in tobacco related COPD. The
(See figure on previous page.)
Fig. 2 Significant correlations between cytokines and spirometric data or cells in the COPD patients with the history of smoking. a: Correlation
between FEV1 and sCD40L; r = -0.342, p = 0.044. b: Correlation between FEV1 and IL-1α; r = -0.314, p = 0.046. c: Correlation between FEV1 and IL-
1β; r = -0.536, p = 0.0009. d: Correlation between sCD40L and FEV/FVC; r = -0.571, p = 0.003. e: Correlation between IL-1α and FEV/FVC; r = -0.227,
p = 0.039. f: Correlation between IL-1β and FEV/FVC; r = -0.621, p < 0.0001. g: Correlation between IL-1α and clinical stage; r = 0.295, p = 0.045. h:
Correlation between clinical stage and IL-1β; r = 0.384, p = 0.022. i: Correlation between sCD40L and neutrophils ; r = 0.531, p = 0.004. j: Correlation
between IL-1β and neutrophils; r = 0.406, p = 0.036. k: Correlation between IL-1α and lymphocytes; r = 0.383, p = 0.025. l: Correlation between
sCD40L and monocytes; r = 0.334, p = 0.047. Legend: FEV1: forced expiratory volume in the first second. FVC: forced vital capacity. IL: interleukin.
sCD40L: soluble cluster differentiation 40 ligand. r = Coefficient of correlation: - When r is positive, this means that the concentration of cytokine
and the values of spirometric data (or the concentration of cells) vary in the same direction. - When r is negative, this means that the
concentration of cytokine and the value of spirometric data (or concentration of cells) vary in the opposite direction. p = significance threshold: -
If p is greater than 0.05, the correlation is not significantly different. - If p is less than or equal to 0.05, the correlation is statistically significant
Fig. 3 Significant correlations between cytokines and spirometric data or cells in the post-TB airflow obstruction patients. a: Correlation between
FEV1 and IL-1α; r = -0.286, p = 0,047. c: Correlation between FEV/FVC and IL-1α: r = -0.552, p = 0.003. d: Correlation between clinical stage and IL-17;
r = 0.489, p = 0.013. e: Correlation between IL-6 and clinical stage; r = 0.401, p = 0.047. f: Correlation between TNF-α and FEV/FVC; r = 0.588, p =
0.007. g: Correlation between MIP-1α and lymphocytes; r = 0.4294, p = 0.0461. Legend: FEV1 = forced expiratory volume in the first second. FVC =
forced vital capacity. IL = interleukin. MIP = macrophage inflammatory protein. r = correlation test. r = Coefficient of correlation: - When r is
positive, this means that the concentrations of cytokine and the values of spirometric data (or the concentrations of cells) vary in the same
direction. - When r is negative, this means that the concentrations of cytokine and the value of spirometric data (or concentrations of cells) vary
in the opposite direction. p = significance threshold: - If p is greater than 0.05, the correlation is not significantly different. - If p is less than or
equal to 0.05, the correlation is statistically significant
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function of IL-1α was previously investigated in mice,
which indicated a high level of IL-1α 4 days after expos-
ure to cigarette smoke, during stable COPD and during
exacerbations [18]. IL-1α may promote neutrophils infil-
tration into the airway. The study performed by Fernando
et al. (2011) showed a significant correlation between IL-
1α and IL-1β levels and chemokine in the sputum of mice
with COPD. IL-1α and IL-1β could therefore promote the
production of other pro-inflammatory cytokines.
The higher IL-6 in COPD patients with a history of
smoking compared to COPD patients who previously
had TB could be related to two facts: either IL-6 does
not significantly interfere with post-TB airflow obstruc-
tion (there was no difference between the COPD/post-
TB subgroup and the control group in the level of IL-6),
or this result could be linked to the fact that most
COPD/post-TB subjects were at a less advanced clinical
stage (the results showed a positive correlation between
the clinical stage and the concentration of IL-6). Suley-
man et al. [19] found that the clinical stage of COPD
was correlated with the concentration of IL-6.
Levels of TNF-α were statistically significantly higher in
the COPD patients with a history of smoking. Generally,
the secretion of TNF-α in COPD is induced by tobacco
smoke and maintained by the chronic inflammation
process [20]. TNF-α has multiple pro inflammatory ac-
tions [21]. TNF-α stimulates the migration of monocytes/
macrophages and neutrophils into the epithelial airways.
Macrophages and induced epithelial cells produce GRO,
MIP-1 and IL-8 [22]. TNF-α and IL-8 cause degranulation
of neutrophils and shortness of breath with the produc-
tion of free radicals that causes epithelial and matrix dam-
age. In addition, TNF-α has also been reported to have a
direct effect on epithelial cells [22], being capable of indu-
cing hypersecretion of mucus, resulting in cell death and
emphysematous lesions and contributing to the deterior-
ation of the clinical state seen in COPD correlated with
weight loss [3].
Since Mycobacterium tuberculosis is no longer present
in the post-TB airflow obstruction patients, there is no
real inducing element of TNF-α, which could justify its
low concentration in COPD/post-TB patients.
IL-17 concentrations in both subgroups of COPD pa-
tients were higher compared to the control group. During
post smoking COPD, IL-17 plays a role in T cell prolifera-
tion, activation of fibroblasts, endothelials and epithelial
cells, induces release of cytokines (IL-6, GM-CSF) and
activation of neutrophils [23, 24]. IL-17 is involved in the
proliferation of T lymphocytes, activation of fibroblasts,
endothelial and epithelial cells. IL-17 induces the release
of Il-6 and IL-8 [25]. The fact that the IL-17 concentration
is high in the COPD/post TB subgroup could be justified
by the fact that this cytokine also plays an important role
in post-TB AFO as in COPD related to tobacco.
Regarding MIP-1β, a higher concentration was noted in
the COPD patients with a history of tobacco compared to
the control group. MIP-1β is a chemokine that induces
lymphocyte migration and recognizes CCR5 receptors in
T cells and macrophages [26]. Some studies have shown
that MIP-1β is essentially produced by macrophages [26].
Our results indicated a higher concentration among the
smokers certainly because these patients were at a more
advanced stage of the disease (the lesions caused by the
destruction of the airways were more severe), and this
could be related to emphysema that characterizes COPD.
MIP-1β plays an important role in the IgG immune com-
plex induced by acute lung injury [27]. This chemokine
was not strongly expressed in the post-TB airflow obstruc-
tion patients. This could be explained by the fact that in
this subgroup most patients were at a less advanced stage
of the disease; so emphysematous damage should be lower
compared to smokers.
The high expression of IL-8 in smoker patients has
certainly been induced by cigarette smoke, and is
maintained by chronic intoxication of the airways as is
the case in the studies conducted by Becker and col-
leagues [28]. Studies report that myeloperoxidase and
elastase released by activated neutrophils amplify the
production of IL-8 [29], which would justify its high
concentration in COPD/tobacco patients who have a
higher number of neutrophils. Our recent study on the
same population showed that the neutrophil count was
higher in post-smoking COPD compared to the post-
TB form [30]. GRO is an important chemotactic
mediator of neutrophils, endothelial cell adhesion and
degranulation. Its chemotactic role in neutrophils has
been demonstrated by some studies based on the ani-
mal model [29]. It would play the same role as IL-8 in
tobacco related COPD. The concentration of GRO was
rather high in the post-TB airflow obstruction patients
(post-TB AFO). Since this chemokine is high in the
sputum of patients with a history of TB, it could be the
chemotactic marker of neutrophils in post-TB AFO
such as IL-8 in the post smoking COPD form. How-
ever, the preferential involvement of the GRO in post-
TB AFO remains to be clarified.
SCD40L bind to CD40 of monocytes to promote their
adhesion to the vascular endothelium, and to endothelial
cells to activate them. Some studies have found high
concentrations of sCD40L in certain diseases such as se-
vere sepsis [31] and in coronary syndrome [32], but, the
studies has yet not shown the role of sCD40L in COPD
neither in humans nor in the animal model. It is possible
that sCD40L is an important marker in COPD and could
play a particular role in the pathogenesis of post-TB
airflow obstruction through its high concentration.
VEGF was strongly expressed in the sputum of COPD
patients with a smoking history compared to the control
Guiedem et al. BMC Immunology           (2020) 21:52 Page 8 of 11
group, and not expressed in the COPD patients with
anterior TB. VEGF is a growth factor involved in angio-
genesis (forming new preexisting vessel growths) in
asthma. As in asthma, VEGF would be involved in the
mechanism of bronchial vascular remodeling during
COPD. Kanazawa et al. [33] found an increased level of
VEGF in the induced sputum of subjects with COPD.
Kranenburg et al. [34] showed that COPD was associ-
ated with increased VEGF expression in the bronchi and
bronchial and alveolar epithelium. Two studies con-
ducted by Sichelstiel et al. [35] and Esmaeil et al. [16]
found higher concentrations of VEGF in the sputum of
COPD patients compared to healthy subjects. Calabrese
et al., [27] found an association between increased bron-
chial vasculature and cellular expression of VEGF and
that VEGF receptor blockade induced apoptosis of
alveolar endothelial cells. The high pulmonary concen-
trations of VEGF in COPD, and more particularly in
smokers, may therefore reflect two effects: either a
regulatory effect upstream of the irritations caused by
tobacco smoke, or an attempt to repair epithelial damage
related to pathogenesis and emphysema in COPD [33].
Conclusion
The objective of the study was to compare the profile of
certain cytokines in COPD/tobacco and COPD/post-TB
patients. We reached the following conclusions: COPD
related to tobacco use is more severe than the post-TB
form. The pathogenesis of COPD in patients with a his-
tory of smoking involves several cytokines in the local
pathway such as IL-1α, IL-1β, IL-6, IL-17, TNF-α, IL-8,
MIP-1β and VEGF. In contrast the pathogenesis of the
post-TB form seems to imply fewer inflammatory




Study participants were recruited from the Yaoundé
Jamot Hospital (YJH) from February 2016 to July 2017.
YJH is the main and biggest center in Cameroon
specializing in the management of respiratory disorders.
Participants constituted COPD patients and healthy
non-smokers who served as controls. COPD participants
were chosen among patients consulting at the YJH and
who had been diagnosed by a pneumologist. COPD pa-
tients comprised two sub-groups: patients with a history
of smoking (COPD/tobacco) and patients with post-TB
airflow obstruction (post-TB AFO or COPD/post TB).
The COPD/tobacco group had clinical signs of COPD
during active smoking and they stopped to smoke once
they understood that cigarette smoke was the cause of
their disease. Post-TB AFO patients had previously one
or more episode TB without smoking. Participants were
eligible for the study if they gave written informed con-
sent for participation, including consent for HIV testing.
Patients were excluded if they had active TB, or were
physically or mentally unable to perform a respiratory
function test. The work received ethical clearance from
the Cameroon National Ethical Committee of Research
for Human Health (N° 2016/06/772/CE/CNERSH/SP).
Data and sample collection
Once the pneumologist had diagnosed an eligible patient
with COPD, the spirometric results of the patient were
extracted from his/her medical record. The history of
TB or smoking was also extracted from patients’medical
records and confirmed by each patient. Spirometric
measurements for the control group were done with the
turbine pneumotachograph (SpiroUSB, Care fusion,
Yorba Linda, USA) following the American Thoracic
Society standard to ensure that participants did not have
any respiratory problems. Sputum samples were col-
lected from each participant. Samples were transported
at ambient conditions in a coolbox to the Center for the
Study and Control of Communicable Diseases of the
Faculty of Medicine and Biomedical Sciences, University
of Yaoundé I. Upon receipt in the laboratory, cell counts
(neutrophils, macrophages and lymphocytes) were per-
formed after staining of the smear with May-Grunwald
Giemsa and read by light microscopy. After the cell
counts, the sputum was liquefied by mixing with phos-
phate buffered saline (PBS). The sputum was centrifuged
at 2000 rpm for 10 min, and the supernatant was ali-
quoted and stored at − 80 °C until cytokine analyses. The
cytokine analyses were performed by the Luminex tech-
nique at Stellenbosch University Immunology Research
Group laboratory (SUN-IRG), university of Stellenbosch,
Cape Town, South Africa.
Luminex multiplex immunoassay
The concentrations of 29 cytokines including pro-
inflammatory cytokines (interleukin: IL-1β, IL-1α, IL-2,
IL-4, IL-6, IL-7α, IL-12p70, IL-12p40, IL-15 and IL-17A,
tumor necrosis factor: TNF-α and TNF-β, and inter-
feron: IFN-α and IFN-ɣ), chemokines (IL-8, growth
regulated oncogene: GRO, interferon-inductible protein:
IP-10, macrophage inflammatory protein: MIP-1α and
MIP-1β, monocyte chemiotactic protein: MCP-1, regulated
on activation normal T cells expressed and secreted: RANT
ES, soluble CD40 ligand: sCD40L and macrophage-derived
chemokine: MDC); anti-cytokines (IL-10 and IL-1receptor
antagonist: RA) and growth factors (ganulocyte-colony
stimulating Factor: G-CSF, granunocyte macrophage-CSF:
GM-CSF, platelet-derived growth factor: PDGF and vascu-
lar endothelial growth factor: VEGF), were investigated in
sputum samples from all study participants. Reagents were
purchased from Merck Millipore, Billerica, Massachusetts,
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United States of America (USA). Experiments were per-
formed and read on the Bio-Plex platform (Bio-Rad, USA),
with the Bio-Plex Manager Software version 6.1 used for
bead acquisition and analysis.
Statistical analyses
The data was analyzed using Graphpad Prism version 5
(GraphPad Software Inc., California, USA). Quantitative
variables were presented as mean (± standard error) when
the distribution was considered normal; if not they were
represented by their median (± interquartile interval). A
chi-square test was used to compare proportions. The
Student’s t-test or Mann-Whitney U test was used to
compare means or medians respectively between two
groups. The ANOVA test was used to compare the quan-
titative variables between three groups at the same time.
The Pearson’s chi squared test was used to test the associ-
ation between the concentrations of cytokines and spiro-
metric data. P-values ≤0.05 were considered significant.
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